Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility$350 million initial term loan funded at close and up to an additional $150 million available ...

Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.

Madrigal Pharmaceuticals shares rose after the biopharmaceutical company received a U.S. patent for its Rezdiffra treatment. Shares were up 11% at $345.24 Wednesday. The stock has been up 12.8% this ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...

The extended patent protection strengthens Madrigal’s market position by preventing generic competition for over two decades, ...

Guardforce AI Co., Limited (Nasdaq: GFAI, GFAIW) ('Guardforce AI” or the 'Company”), a global integrated security solutions ...

• Provides Protection Through Sept. 2044; Will Be Listed in FDA’s Orange Book ...

In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

How could Rezdiffra’s first-mover advantage in NASH treatment benefit Madrigal? According to InvestingPro analysis, analysts maintain a strong buy consensus with a high target of $540, representing ...